To determine if anti-IFN-γ mAb treatment would be efficacious when Th1 cells predominate, i.e., mimicking conditions when patients are commonly diagnosed, we developed a modified model of anti-MPO GN, whereby disease is triggered in mice at day 28 when Th1 immune responses are well established. This evidence concerns the gene IFNG and ganglioneuroma.